Summary of Expertise, Experience, and Affiliations and Interests for the Scientific Advisory Panel on Anti-Infective Therapies (SAP-AIT)

Purpose

The following table summarizes the information about expertise, experience, and affiliations and interests relevant to the Scientific Advisory Panel on Anti-Infective Therapies (SAP-AIT) mandate declared by panel members. Health Canada considered these declarations as part of the selection process. The Health Products and Food Branch has made this summary available as part of its commitment to be transparent about the membership of its advisory bodies.

Assessment of affiliations and interests prior to each meeting

Prior to each panel meeting, Health Canada assesses members' affiliations and interests, including direct financial interests, as they may apply to agenda items for discussion. Depending on the nature of the member's affiliations and interests, the Chair of the panel in consultation with other members of the panel may limit the participation of a member in the meeting or ask him/her to make a verbal statement of affiliations and interests at the beginning of the meeting. Members' affiliations and interests are reviewed on an annual basis and updated as required based on changes in the status of their affiliations and interests.

In accordance with the Health Products and Food Branch Review of Regulated Products: Policy on Public Input and Guidance on Advisory Bodies, a person with a direct financial interest in the outcome of a review of a regulated product may be a member of an advisory body whose broader mandate encompasses matters of policy, management, or program development. However, such a member would not be asked to participate in any discussion, formulation of advice, or recommendations to Health Canada relating to that review.

Indicated Perspective/Sector and Expertise/Experience

Perspective/Sector:

  • Health professional
  • Academia
  • Research

Expertise/Experience:

  • Infectious diseases
  • Pharmacy
  • Family medicine

Direct financial interests
1. Current employment, investments in companies, partnerships, equity, royalties, joint ventures, trusts, real property, stocks, shares, or bonds with the regulated industry.

Indirect financial interests
2. Within the past five years, payment from the regulated industry for work done or being done, including past employment, contracts, or consulting; or financial support including research support, personal education grants, contributions, fellowships, sponsorships, and honoraria.Footnote 1
3. Within the past five years, materials, discounted products, gifts, or other benefits, or attendance at meetings where all or part of the travel and accommodation costs were provided by the regulated industry.Footnote 2
4. Within the last three years, grants or other funding from the regulated industry to any of the organizations where you are currently employed or participate in internal decision making.Footnote 3

Intellectual interests
5. Within the last five years, any formal advice or opinion to industry, a government organization, or a non-government organization.
6. Within the last five years, any published or publicly stated point of view.
7. Current professional or volunteer affiliations such as membership of professional societies, lobbying, public interest, or advocacy groups.

Other affiliations and interests
8. Any other affiliations and interests or potential circumstances that might give a well-informed member of the public reasonable grounds for concern regarding the integrity and objectivity of your participation.

Name and Indicated Sector/Perspective and Expertise/Experience Summary of Responses
Dr. Gerald Evans (Chair) Perspective/Sector
Infectious Disease

Expertise/Experience
Medicine, Biomedical and Molecular Sciences, Pathology and Molecular Medicine
1) NO 2) YES 3) NO 4) NO 5) NO 6) NO 7) YES 8) NO
Comments:
Has participated in two multi-centre registered clinical trials funded by industry. Participates in professional scientific societies who may have an interest in the mandate and work of SAP-AIT.
Dr. Andrew Morris Perspective/Sector
Infectious Disease

Expertise/Experience
Epidemiology
1) NO 2) NO 3) NO 4) NO 5) NO 6) NO 7) YES 8) NO
Comments:
Participates in a professional scientific society and has a volunteer association who may have an interest in the mandate and work of SAP-AIT.
Dr. Edith Blondel-Hill Perspective/Sector
Medical Microbiologist/Infectious Disease Specialist

Expertise/Experience
Internal Medicine, Infectious Disease, Medical Microbiology
1) NO 2) NO 3) NO 4) NO 5) NO 6) YES 7) YES 8) NO
Comments:
Has made a public statement regarding Quinolone use in a publication on issues of relevance to the advisory body's mandate. Participates in professional scientific societies who may have an interest in the mandate and work of SAP-AIT.
Dr. John Conly Perspective/Sector
Infectious Disease

Expertise/Experience
Antibiotic Resistance, Hospital epidemiology
1) YES 2) YES 3) YES 4) YES 5) YES 6) YES 7) YES 8) NO
Comments:
Has equity in common shares of a mixed portfolio of companies in the regulated industry that are of relevance to the mandate of the advisory body. Has received compensation from the regulated industry for consultation work and lectures given regarding his research. Has received benefits from the regulated industry in the form of travel compensation for consulting and lectures given regarding his research. The University of Calgary has been awarded grants from the regulated industry to support the panel member's research consultant and clinical trial primary investigator work. Has worked as a consultant on the Canadian response to antibiotic resistance in service to the Office of the Auditor General of Canada from 2014 to 2015. Has volunteered as an expert witness for the Senate Standing Committee on February 13, 2014 where the topics of the loss of antibiotics and antibiotic resistance were discussed. Has published articles in peer reviewed journals on antimicrobial resistance, new antibiotics and antimicrobial resistance programs in Canada. The Panel member is affiliated with many professional scientific societies that may have an interest in the mandate and work of SAP-AIT.
Dr. Susan Fryters Perspective/Sector
Pharmacy

Expertise/Experience
Antimicrobial utilization and evaluation
1) NO 2) NO 3) NO 4) NO 5) YES 6) NO 7) YES 8) NO
Comments:
Volunteered to participate via WebEx the National Hospital Pharmacist Advisory Board Meeting, sponsored by a member of the regulated industry that addressed new advances in the treatment of MRSA infections. Received no compensation. Is a member of the Canadian Society of Hospital Pharmacists (CSHP), the Alberta College of Pharmacy (ACP); volunteers on the executive committee and is a co-author and editor on a publication on issues of relevance to SAP-AIT.
Dr. Tim Lau Perspective/Sector
Pharmacy / Infectious Disease

Expertise/Experience
Antimicrobial stewardship and consumption, Vaccine utilization
1) NO 2) NO 3) NO 4) NO 5) NO 6) NO 7) YES 8) NO
Comments:
Is a member of a Provincial working group that promotes appropriate antimicrobial use across the province. Is affiliated with a professional scientific society that has an interest in the mandate and work of SAP-AIT.
 
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: